Futura Medical plc, a consumer healthcare company specializing in the development and global commercialization of innovative sexual health products, has announced the successful passing of all resolutions at its Annual General Meeting. Shareholders voted on various resolutions, including the adoption of the annual report and accounts, the appointment of directors, the re-appointment of the auditor, and the authorization of the directors to determine the auditor's remuneration.
The voting results indicated overwhelming support for the resolutions, with the majority of votes in favor of each proposal. The company's total voting rights were reported to be 301,863,641 ordinary shares of 0.2p each, with no shares held in treasury.
Futura Medical's lead product, Eroxon, is a clinically proven topical gel developed for the treatment of Erectile Dysfunction (ED). It is the only over-the-counter topical gel treatment for ED that helps men achieve an erection in ten minutes, addressing significant unmet needs in the ED market. The product's differentiation and ability to cater to a substantial portion of the male population affected by ED position it as a promising solution in the sexual health products market.
The prevalence of ED, affecting 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40, underscores the substantial market opportunity for Futura Medical's innovative products.
For further information, the company's contacts and additional details can be found on their official website.